174 related articles for article (PubMed ID: 21217768)
1. The association of aromatase (CYP19) gene variants with sperm concentration and motility.
Lazaros L; Xita N; Kaponis A; Hatzi E; Plachouras N; Sofikitis N; Zikopoulos K; Georgiou I
Asian J Androl; 2011 Mar; 13(2):292-7. PubMed ID: 21217768
[TBL] [Abstract][Full Text] [Related]
2. Semen quality is influenced by androgen receptor and aromatase gene synergism.
Lazaros L; Xita N; Takenaka A; Sofikitis N; Makrydimas G; Stefos T; Kosmas I; Zikopoulos K; Hatzi E; Georgiou I
Hum Reprod; 2012 Dec; 27(12):3385-92. PubMed ID: 23001776
[TBL] [Abstract][Full Text] [Related]
3. Evidence for association of sex hormone-binding globulin and androgen receptor genes with semen quality.
Lazaros L; Xita N; Kaponis A; Zikopoulos K; Sofikitis N; Georgiou I
Andrologia; 2008 Jun; 40(3):186-91. PubMed ID: 18477206
[TBL] [Abstract][Full Text] [Related]
4. Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation.
Lazaros LA; Hatzi EG; Xita NV; Makrydimas GV; Kaponis AI; Takenaka A; Kosmas IP; Sofikitis NV; Stefos TI; Zikopoulos KA; Georgiou IA
J Assist Reprod Genet; 2012 Feb; 29(2):203-9. PubMed ID: 22089263
[TBL] [Abstract][Full Text] [Related]
5. Association of paraoxonase gene polymorphisms with sperm parameters.
Lazaros LA; Xita NV; Hatzi EG; Kaponis AI; Stefos TJ; Plachouras NI; Makrydimas GV; Sofikitis NV; Zikopoulos KA; Georgiou IA
J Androl; 2011; 32(4):394-401. PubMed ID: 21127310
[TBL] [Abstract][Full Text] [Related]
6. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype.
Xita N; Georgiou I; Lazaros L; Psofaki V; Kolios G; Tsatsoulis A
Eur J Endocrinol; 2008 Jun; 158(6):861-5. PubMed ID: 18505907
[TBL] [Abstract][Full Text] [Related]
7. Association of TNFα, TNFR1, and TNFR2 polymorphisms with sperm concentration and motility.
Lazaros LA; Xita NV; Chatzikyriakidou AL; Kaponis AI; Grigoriadis NG; Hatzi EG; Grigoriadis IG; Sofikitis NV; Zikopoulos KA; Georgiou IA
J Androl; 2012; 33(1):74-80. PubMed ID: 21350240
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic variation in CYP19 and the risk of breast cancer.
Baxter SW; Choong DY; Eccles DM; Campbell IG
Carcinogenesis; 2001 Feb; 22(2):347-9. PubMed ID: 11181459
[TBL] [Abstract][Full Text] [Related]
9. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
[TBL] [Abstract][Full Text] [Related]
10. CYP19 gene variants affect the assisted reproduction outcome of women with polycystic ovary syndrome.
Lazaros L; Xita N; Hatzi E; Takenaka A; Kaponis A; Makrydimas G; Sofikitis N; Stefos T; Zikopoulos K; Georgiou I
Gynecol Endocrinol; 2013 May; 29(5):478-82. PubMed ID: 23461365
[TBL] [Abstract][Full Text] [Related]
11. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women.
Ribeiro FS; de Amorim LM; de Almeida Simão T; Mendonça GA; de Moura Gallo CV; Pinto LF
Toxicol Lett; 2006 Jun; 164(1):90-5. PubMed ID: 16406421
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the association between the CYP19 Tetranucleotide (TTTA)n polymorphism and polycystic ovarian syndrome(PCOS) in Han Chinese women.
Hao CF; Zhang N; Qu Q; Wang X; Gu HF; Chen ZJ
Neuro Endocrinol Lett; 2010; 31(3):370-4. PubMed ID: 20588246
[TBL] [Abstract][Full Text] [Related]
13. Association of the (TTTA)n repeat polymorphism of CYP19 gene with bone mineral density in Greek peri- and postmenopausal women.
Markatseli AE; Lazaros L; Markoula S; Kostoulas H; Sakaloglou P; Tigas S; Georgiou I; Tsatsoulis A
Clin Endocrinol (Oxf); 2014 Jul; 81(1):38-44. PubMed ID: 24621381
[TBL] [Abstract][Full Text] [Related]
14. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism.
Gennari L; Masi L; Merlotti D; Picariello L; Falchetti A; Tanini A; Mavilia C; Del Monte F; Gonnelli S; Lucani B; Gennari C; Brandi ML
J Clin Endocrinol Metab; 2004 Jun; 89(6):2803-10. PubMed ID: 15181061
[TBL] [Abstract][Full Text] [Related]
15. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age.
Van Pottelbergh I; Goemaere S; Kaufman JM
J Clin Endocrinol Metab; 2003 Jul; 88(7):3075-81. PubMed ID: 12843146
[TBL] [Abstract][Full Text] [Related]
16. A rare CYP19 (aromatase) variant may increase the risk of breast cancer.
Kristensen VN; Andersen TI; Lindblom A; Erikstein B; Magnus P; Børresen-Dale AL
Pharmacogenetics; 1998 Feb; 8(1):43-8. PubMed ID: 9511180
[TBL] [Abstract][Full Text] [Related]
17. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.
Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS
Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of follicle-stimulating hormone receptor and androgen receptor gene variants on semen quality.
Lazaros L; Xita N; Takenaka A; Sofikitis N; Makrydimas G; Stefos T; Kosmas I; Zikopoulos K; Hatzi E; Georgiou I
Andrologia; 2013 Oct; 45(5):339-44. PubMed ID: 23013557
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
Healey CS; Dunning AM; Durocher F; Teare D; Pharoah PD; Luben RN; Easton DF; Ponder BA
Carcinogenesis; 2000 Feb; 21(2):189-93. PubMed ID: 10657957
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
Tofteng CL; Kindmark A; Brändström H; Abrahamsen B; Petersen S; Stiger F; Stilgren LS; Jensen JE; Vestergaard P; Langdahl BL; Mosekilde L;
Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
